Login or sign up
For business
Average ratingAverage
3.4/ 5

Based on 11 reviews

527%
436%
39%
20%
127%
Ask AI

Ask Trustburn about Grünenthal

Based on 11 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Jasna Karkin
Reviews 1

Grünenthal is an average company. I have been a customer for a couple of years now and while their products are okay, I have found better options elsewhere. The customer service is decent, but nothing exceptional. Overall, I would give Grünenthal a rating of average.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. Our purpose is to change lives for the better – and innovation is our passion. We focus our activities on moving towards our vision of a world free of pain.

Grünenthal: A Global Leader in Pain Management and Related Diseases

Grünenthal is a renowned pharmaceutical company that specializes in pain management and related diseases. With a strong focus on innovation, the company has been at the forefront of developing new treatments for chronic pain, neuropathic pain, cancer pain, and other conditions that affect millions of people worldwide.

Founded in 1946 by Hermann Wirtz, Grünenthal has grown into a global enterprise with operations in more than 30 countries. The company's headquarters are located in Aachen, Germany, where it employs over 2,500 people. Grünenthal also has research and development centers in Europe and the United States.

At Grünenthal, our purpose is to change lives for the better by providing effective solutions for patients suffering from pain. We believe that everyone deserves to live without constant discomfort or limitations caused by their condition. That's why we are committed to developing innovative therapies that can improve quality of life for those affected by chronic or acute pain.

Our approach to drug development is based on scientific excellence and patient-centeredness. We work closely with healthcare professionals and patient organizations to understand their needs and develop treatments that meet their expectations. Our research focuses on identifying new targets for drug discovery as well as improving existing therapies through formulation optimization or combination approaches.

One of our most significant achievements was the development of Tramadol – an opioid-like analgesic used to treat moderate-to-severe pain – which became one of the most prescribed drugs worldwide since its launch in 1977. Today we continue to innovate with products such as Palexia (tapentadol), Nucynta (tapentadol), Qutenza (capsaicin) patches among others.

In addition to our core business activities, we also support various initiatives aimed at improving public health outcomes globally through partnerships with governments & NGOs around the world; this includes access programs designed specifically for low-income countries where access remains limited due to affordability issues.

We recognize that there are many challenges associated with managing chronic pain effectively; however, we remain committed to finding solutions through ongoing research efforts aimed at discovering new therapeutic options while ensuring safety & efficacy standards are met throughout all stages of drug development process - from preclinical studies up until post-marketing surveillance activities.

At Grünenthal innovation is not just a buzzword but rather an integral part of our DNA; it drives us forward every day towards achieving our vision: "A world free from Pain."

Categories
Pharmaceuticals